Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2014. Start Trial.
Date Value
September 30, 2026 677.22M
June 30, 2026 739.82M
March 31, 2026 736.94M
December 31, 2025 714.72M
September 30, 2025 699.19M
June 30, 2025 652.94M
March 31, 2025 649.46M
December 31, 2024 662.32M
September 30, 2024 644.19M
June 30, 2024 640.08M
March 31, 2024 652.39M
December 31, 2023 643.91M
September 30, 2023 650.31M
June 30, 2023 726.36M
March 31, 2023 712.16M
December 31, 2022 690.77M
September 30, 2022 643.30M
June 30, 2022 520.19M
March 31, 2022 479.53M
December 31, 2021 483.91M
September 30, 2021 482.34M
June 30, 2021 459.45M
March 31, 2021 430.07M
December 31, 2020 398.88M
September 30, 2020 364.04M
Date Value
June 30, 2020 376.88M
March 31, 2020 392.21M
December 31, 2019 357.36M
September 30, 2019 345.91M
June 30, 2019 315.81M
March 31, 2019 296.60M
December 31, 2018 294.00M
September 30, 2018 283.91M
June 30, 2018 274.28M
March 31, 2018 255.88M
December 31, 2017 231.64M
September 30, 2017 220.86M
June 30, 2017 209.16M
March 31, 2017 194.06M
December 31, 2016 183.20M
September 30, 2016 177.02M
June 30, 2016 158.02M
March 31, 2016 137.79M
December 31, 2015 114.74M
September 30, 2015 83.48M
June 30, 2015 66.63M
March 31, 2015 54.77M
December 31, 2014 45.76M
September 30, 2014 40.65M
June 30, 2014 34.56M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. 921.08M
AbbVie, Inc. 9.962B
Krystal Biotech, Inc. 53.62M
BridgeBio Pharma, Inc. 536.01M
Alnylam Pharmaceuticals, Inc. 1.559B